Tissue‐type plasminogen activator (tPA) homozygous Tyr471His mutation associates with thromboembolic disease

Yanyi Tao, Jiewen Ma, Yuanzheng Feng, Chenggang Gao, Tingting Wu, Yunqing Xia, Zhipeng Cheng, Yi Zhang, Tingting Liu, Yu Hu, Liang TangMedComm 2023 · DOI

TL;DR

This paper identifies a novel homozygous mutation (Tyr471His) in the tissue-type plasminogen activator (tPA) gene that leads to a significant reduction in fibrinolytic activity and an increased propensity for blood clots (thromboembolic disease). The findings highlight a critical role for the tPA protease domain in efficient plasminogen activation and suggest potential therapeutic avenues for patients with this mutation.

What Problem Does This Paper Address?

The paper addresses the rare occurrence of genetic mutations in the PLAT gene (which encodes tPA) that are linked to venous thromboembolism (VTE). While tPA is a crucial protein for dissolving blood clots (fibrinolysis) and preventing thrombosis, most research has focused on its therapeutic use or general polymorphisms, with limited understanding of how specific pathogenic mutations in the PLAT gene itself can directly cause thrombotic disorders. The study aims to characterize a newly identified homozygous mutation in PLAT, understand its functional impact on tPA, and elucidate the underlying molecular mechanisms contributing to the observed thromboembolic phenotype.

Methods

The researchers employed a multi-faceted approach to investigate the impact of the Tyr471His mutation:

  • Genetic Analysis: DNA sequencing was used to identify the homozygous mutation in the proband and heterozygous carriers in his family.
  • Protein Synthesis and Characterization: Wild-type tPA (tPA-WT) and the mutant tPA (tPA-Y471H) were synthesized in vitro.
  • Binding Assays:
    • Surface Plasmon Resonance (SPR): Used to quantitatively measure the binding affinity of tPA-WT and tPA-Y471H to plasminogen (the precursor to the clot-dissolving enzyme plasmin) and PAI-1 (a tPA inhibitor).
  • Molecular Docking: Computational modeling was used to visualize and analyze the interactions between the tPA protease domain and plasminogen/PAI-1, predicting how the mutation might alter these interactions.
  • Functional Assays:
    • Western Blotting: Assessed the rate of plasminogen conversion to plasmin in the presence of fibrin, mediated by tPA-WT and tPA-Y471H.
  • Turbidity Assay: Measured the time it took for fibrin clots to dissolve (clot lysis time) when treated with tPA-WT or tPA-Y471H.
  • Immunofluorescence Imaging and Agar Plate Assays: Further evaluated the fibrinolytic activity of the mutant tPA.
  • Animal Models:
    • Mutant Mice (PLATH/H): Genetically engineered mice carrying the homologous mutation were created to study the in vivo effects.
  • Inferior Vena Cava (IVC) Stenosis Model: Induced venous thrombosis to assess the propensity for clot formation in mutant mice compared to wild-type controls.
  • Carotid Artery Thrombosis Model: Used FeCl3 to induce arterial injury and measure time to occlusion and tPA release.
  • mRNA Stability Assays: Investigated the half-life of tPA mRNA in endothelial cells to understand potential post-transcriptional regulation affected by the mutation.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • A Novel Pathogenic Mutation: The identification of a homozygous Tyr471His mutation in the PLAT gene as a cause of severe thromboembolic disease is a significant discovery, as such mutations are rare.
  • Protease Domain Cruciality: The mutation's location in the tPA protease domain, rather than the more commonly studied kringle domains, highlights its critical role in plasminogen activation and fibrinolysis.
  • Disrupted Protein Interactions: The mutation significantly impairs tPA's ability to bind plasminogen, primarily by disrupting interactions with the kringle 4 domain of plasminogen. This reduced binding affinity is a key driver of the decreased fibrinolytic function.
  • Reduced mRNA Stability: The mutant tPA mRNA exhibits a shorter half-life, leading to lower overall tPA protein levels and activity, further contributing to impaired fibrinolysis.
  • Translational Relevance: The findings in the mouse model directly correlate with the human proband's condition, validating the mutation's pathogenicity and providing a platform for understanding and potentially treating such disorders.

Key Results

  • Clinical Presentation: The proband presented with recurrent deep vein thrombosis at a young age, despite lacking other common thrombophilias.
  • Binding Affinity: The binding affinity of tPA-Y471H to plasminogen was reduced by approximately one order of magnitude compared to tPA-WT. Binding to PAI-1 was also slightly decreased.
  • Functional Impairment:
    • Plasminogen conversion to plasmin was significantly reduced (64.77% vs. 97.79% for tPA-WT).
  • Clot lysis time was significantly prolonged by tPA-Y471H (38.02 min vs. 21.41 min for tPA-WT).
  • Fibrinolytic activity measured by immunofluorescence and agar plate assays was significantly slower for tPA-Y471H.
  • In Vivo Thrombosis: PLATH/H mice showed a significantly higher rate of venous thrombosis (80% vs. 53% in wild-type mice) and larger thrombus weights and lengths. Arterial thrombosis was also accelerated in mutant mice.
  • tPA Levels: Mutant mice exhibited reduced plasma tPA antigen levels (74.7%) and enzymatic activity (56.8%) compared to wild-type controls.
  • mRNA Half-life: The half-life of tPA mRNA in endothelial cells was significantly shortened in mutant mice.

Limitations and Future Work

  • Limited Clinical Data: The authors acknowledge the rarity of this homozygous mutation and the need for more clinical data to fully understand its incidence and spectrum of disease.
  • Mechanism of Post-Transcriptional Regulation: While the study demonstrates reduced mRNA stability, the precise molecular mechanisms by which the mutation affects post-transcriptional regulation of tPA warrant further investigation.
  • Transcription Level: The possibility that the mutation might also affect tPA transcription level, though less likely given its location, cannot be entirely ruled out and deserves further exploration.
  • Therapeutic Implications: The paper suggests that recombinant tPA (rtPA) might be considered for treating patients with this mutation, but further research is needed to optimize its use and explore other therapeutic strategies to prolong tPA half-life.
  • Broader Impact: Further research is needed to explore the mechanism and significance of the tPA protease domain's interaction with plasminogen, potentially identifying new targets for controlling plasmin generation.

Summary updated

Abstract

Tissue-type plasminogen activator (tPA) encoded by <i>PLAT</i> is a major mediator that promotes fibrinolysis and prevents thrombosis. Pathogenetic mutations in <i>PLAT</i> associated with venous thromboembolism have rarely been reported. Here, we report the first case of a homozygous point mutation c.1411T>C (p.Y471H) in <i>PLAT</i> leading to thromboembolic events and conduct related functional studies. The corresponding tPA mutant protein (tPA-Y471H) and wild-type tPA (tPA-WT) were synthesized in vitro, and mutant mice (<i>PLAT<sup>H/H</sup></i> mice) were constructed. The molecular docking and surface plasmon resonance results indicated that the mutation impeded the hydrogen-bonding interactions between the protease domain of tPA and the kringle 4 domain of plasminogen, and the binding affinity of tPA and plasminogen was significantly reduced with a difference of one order of magnitude. mRNA half-life assay showed that the half-life of tPA-Y471H was shortened. The inferior vena cava thrombosis model showed that the rate of venous thrombosis in <i>PLAT<sup>H/H</sup></i> mice was 80% compared with 53% in wild-type mice. Our data suggested a novel role for the protease domain of tPA in efficient plasminogen activation, and demonstrated that this tPA mutation could reduce the fibrinolysis function of the body and lead to an increased propensity for thrombosis.
BibTeX
@inproceedings{tao2023tissuetype,
  author = {Yanyi Tao and Jiewen Ma and Yuanzheng Feng and Chenggang Gao and Tingting Wu and Yunqing Xia and Zhipeng Cheng and Yi Zhang and Tingting Liu and Yu Hu and Liang Tang},
  title = {{Tissue‐type plasminogen activator (tPA) homozygous Tyr471His mutation associates with thromboembolic disease}},
  booktitle = {MedComm},
  year = {2023},
  doi = {10.1002/mco2.392},
}
Figure